RYTM · NASDAQ · STOCK
Rhythm Pharmaceuticals (RYTM) Stock Analysis
$90.80
52W $74.50 – $122.20
61/100
$6.23B
-29.2
2.01
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is RYTM Bullish or Bearish?
Bullish.
Innellis AI committee rates Rhythm Pharmaceuticals, Inc. (RYTM) Buy with a composite score of 61/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +13.96 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -6.04 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 53.5% yoy -- genuine top-line momentum. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 53.5% YoY -- genuine top-line momentum — Growth
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- News sentiment is positive (+0.50 across 2 articles, 14d) — News
Bear Case
- Price-to-book of 26.5x prices in significant intangible value — Value
- ROE of only -80.5% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 16.0% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
61/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 27%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 26.5x prices in significant intangible value
Growth Analyst
bullish
83
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 53.5% YoY -- genuine top-line momentum
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
52
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
− Bollinger bandwidth of 16.0% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
74
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.50 across 2 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 59.4 to 61.0.
- Recommendation changed from Watch to Buy.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: stance bearish->neutral; score 38->48 (+10).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
31.9
Neutral
MACD Histogram
-0.395
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$79.95
Resistance
$94.55
Bollinger %B
0.18
Inside Bands
Price vs Moving Averages
EMA 9
$92.17
Below
EMA 21
$95.82
Below
EMA 50
$100.08
Below
EMA 200
$98.19
Below
Fundamental Analysis
Valuation
33
Growth
86
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-29.2×
P/B Ratio
28.66×
PEG Ratio
7.30
Dividend Yield
0.00%
52W High
$122.20
52W Low
$74.50
Quality & Growth
ROE
-7278.5%
ROA
-4092.9%
Gross Margin
8900.1%
Operating Margin
-8362.4%
Revenue Growth YoY
—
Debt / Equity
0.02
AI Fundamental Assessment
P/E ratio of -29.2 (inexpensive relative to a 15-40x range); Price-to-book of 28.7x; PEG ratio of 7.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -72.8%; Return on assets of -40.9%; Net margin of -85.6%; Gross margin of 89.0%; Current ratio of 3.45 (healthy short-term liquidity); Debt-to-equity of 0.02; Free cash flow per share is negative (-2.19); Most recent quarter beat estimates by 12.8%; 3 consecutive earnings beats; EPS growth accelerating (-13.7% -> +12.0% QoQ); Analyst estimates rising over recent quarters
Get the Full RYTM Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →